Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene

Nat Biotechnol. 1999 Apr;17(4):343-8. doi: 10.1038/7895.


Tumors require ongoing angiogenesis to support their growth. Inhibition of angiogenesis by production of angiostatic factors should be a viable approach for cancer gene therapy. Endostatin, a potent angiostatic factor, was expressed in mouse muscle and secreted into the bloodstream for up to 2 weeks after a single intramuscular administration of the endostatin gene. The biological activity of the expressed endostatin was demonstrated by its ability to inhibit systemic angiogenesis. Moreover, the sustained production of endostatin by intramuscular gene therapy inhibited both the growth of primary tumors and the development of metastatic lesions. These results demonstrate the potential utility of intramuscular delivery of an antiangiogenic gene for treatment of disseminated cancers.

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Collagen / biosynthesis
  • Collagen / genetics*
  • Collagen / pharmacology
  • Endostatins
  • Female
  • Genetic Therapy*
  • Lung Neoplasms / pathology
  • Lung Neoplasms / secondary
  • Lung Neoplasms / therapy
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Muscle, Skeletal / metabolism*
  • Neoplasm Metastasis / prevention & control*
  • Neoplasms, Experimental / blood supply*
  • Neoplasms, Experimental / pathology
  • Neoplasms, Experimental / therapy*
  • Neovascularization, Pathologic / drug therapy
  • Neovascularization, Physiologic / drug effects
  • Peptide Fragments / biosynthesis
  • Peptide Fragments / genetics*
  • Peptide Fragments / pharmacology


  • Antineoplastic Agents
  • Endostatins
  • Peptide Fragments
  • Collagen